Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles N. York II sold 8,078 shares of the business's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $17.85, for a total value of $144,192.30. Following the transaction, the chief financial officer now owns 217,293 shares of the company's stock, valued at approximately $3,878,680.05. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Day One Biopharmaceuticals Price Performance
Shares of Day One Biopharmaceuticals stock opened at $17.17 on Friday. The stock has a 50-day simple moving average of $15.45 and a 200-day simple moving average of $14.02. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -7.21 and a beta of -1.44.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). As a group, equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.
Wall Street Analyst Weigh In
Dems have chosen Biden replacement?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
DAWN has been the topic of a number of research reports. The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating on the stock in a report on Tuesday, February 27th. Piper Sandler reaffirmed an "overweight" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Needham & Company LLC boosted their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, April 24th. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. Finally, Oppenheimer reiterated a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $39.33.
View Our Latest Stock Report on DAWN
Institutional Trading of Day One Biopharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. First Turn Management LLC acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth about $24,834,000. TimesSquare Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 45.8% in the fourth quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company's stock valued at $24,325,000 after acquiring an additional 523,455 shares during the period. Braidwell LP boosted its position in shares of Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company's stock valued at $61,547,000 after acquiring an additional 500,000 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company's stock worth $30,935,000 after acquiring an additional 472,654 shares during the last quarter. Finally, Superstring Capital Management LP bought a new position in Day One Biopharmaceuticals during the fourth quarter worth $5,543,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
